Hyperglycemia as a symptom of neuroleptic malignant syndrome

Human Psychopharmacology

Volumn 11, Issue 2, 1996, Pages 137-138

  Ishida, M ^a,b   Otani, K ^a   Kaneko, S ^a   Ishida, H ^c   Kawashima, S ^b,c  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b Sanraku Hospital   (Japan)

^c Murakami Hospital   (Japan)

Author keywords

central hypodopaminergic state; hyperglycemia; neuroleptic malignant syndrome

Indexed keywords

BROMPERIDOL; GLIBENCLAMIDE; HALOPERIDOL; INSULIN;

AGED; ARTICLE; CASE REPORT; DIABETES MELLITUS; FEMALE; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; NEUROLEPTIC MALIGNANT SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY;

EID: 0029866171     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199603)11:2<137::AID-HUP767>3.0.CO;2-P     Document Type: Article

References (10)

1. Addonizio, G. and Susman, V. L. (1991). Neuroleptic Malignant Syndrome. A Clinical Approach. Mosby Year Book, Inc., St. Louis.
2. Balzan, M. and Cacciottolo, J. M. (1992). Neuroleptic malignant syndrome presenting as hyperosmolar non-ketotic diabetic coma. British Journal of Psychiatry, 161, 257-258.
3. de Boer, C. and Gaete, H. P. (1992). Neuroleptic malignant syndrome and diabetic keto-acidosis. British Journal of Psychiatry, 161, 856-858.
4. Frohman, L. A. (1988). Neuroendocrine regulation and its disorders. In: Textbook of Medicine, 18th edn, Wyngaarden, J. B. and Smith, L. H., Jr. (Eds), W. B. Saunders Company, Philadelphia, pp. 1280-1381.
5. Lazarus, A., Mann, S. C. and Caroff, S. N. (1989). The Neuroleptic Malignant Syndrome and Related Conditions. American Psychiatric Press, Inc., Washington, DC.
6. Otani, K., Horiuchi, M., Kondo, T., Kaneko, S. and Fukushima, Y. (1991a). Is the predisposition to neuroleptic malignant syndrome genetically transmitted. British Journal of Psychiatry, 158, 850-853.
7. Otani, K., Mihara, K., Okada, M., Kaneko, S. and Fukushima, Y. (1991b). Crossover reaction between haloperidol and amoxapine for NMS. British Journal of Psychiatry, 159, 889.
8. Otani, K., Mihara, K., Kondo, T., Okada, M., Kaneko, S. and Fukushima, Y. (1992). Treatment of neuroleptic malignant syndrome with levodopa. Human Psychopharmacology, 7, 217-221.
9. Sandyk, R., Kay, S. R., Awerbuch, G. I. and Iacono, R. P. (1991). Risk factors for neuroleptic-induced movement disorders. International Journal of Neuroscience, 61, 149-188.
10. Sandyk, R. (1993). The relationship between diabetes mellitus and Parkinson's disease. International Journal of Neuroscience, 69, 125-130.